GERNON CORPORATION INVESTORS: Contact Robbins LLP to Lead the Class Action Against GERN
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: GlobeNewswire
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Geron Corporation (NASDAQ: GERN) securities between June 7, 2024 to February 25, 2025. Geron is a commercial-stage biopharmaceutical company with a focus on blood cancer. Geron’s primary product is a telomerase inhibitor, imetelstat, which the Company sells under the brand name, Rytelo. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Geron Corporation (GERN) Misled Investors Regarding the Launch and Potential Growth of Rytelo According to the complaint, during the class period, defendants failed to disclose to investors thatGeron’s optimistic reports of Rytelo’s launch success and potential growth fell short of reality; the impacts of seasonality, existing compe
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines [Seeking Alpha]Seeking Alpha
- Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation [Yahoo! Finance]Yahoo! Finance
- Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value CreationGlobeNewswire
- Geron (NASDAQ:GERN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.MarketBeat
GERN
Earnings
- 11/5/25 - In-Line
GERN
Sec Filings
- 12/15/25 - Form 144
- 11/7/25 - Form 10-Q
- 11/5/25 - Form 8-K
- GERN's page on the SEC website